Motohide Uemura

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen et al. · New England Journal of Medicine · 2019 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +6

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Brian I. Rini, Thomas Powles, Michael B. Atkins et al. · The Lancet · 2019 · 1K citations

Medicine, Oncology, Pharmacology +13

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Robert J. Motzer, Paul B. Robbins, Thomas Powles et al. · Nature Medicine · 2020 · 522 citations · Full text

Medicine, Oncology, Pharmacology +15

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Association of a novel long non‐coding RNA in <i>8q24</i> with prostate cancer susceptibility

Suyoun Chung, Hidewaki Nakagawa, Motohide Uemura et al. · Cancer Science · 2010 · 286 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17